State of the art in hereditary muscle channelopathies

Acta Myologica

Volumn 29, Issue OCTOBER, 2010, Pages 343-350

  Jurkat Rott, K ^a   Lehmann Horn, F ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Central core disease; Congenital myasthenic syndromes; Non dystrophic myotonias; Periodic paralyses; Susceptibility to malignant hyperthermia

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETAZOLAMIDE; ALDOSTERONE ANTAGONIST; ANTIARRHYTHMIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; CHOLINESTERASE INHIBITOR; DANTROLENE; EDROPHONIUM; EPHEDRINE; FLECAINIDE; FLUOXETINE; HYDROCHLOROTHIAZIDE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MEXILETINE; POTASSIUM SPARING DIURETIC AGENT; PROPAFENONE; PYRIDOSTIGMINE; SALBUTAMOL;

ARTICLE; BECKER MUSCULAR DYSTROPHY; CALCIUM CHANNELOPATHY; CENTRAL CORE DISEASE; CONGENITAL MYASTHENIC SYNDROME; GENE MUTATION; HUMAN; HYPOKALEMIC PERIODIC PARALYSIS; MALIGNANT HYPERTHERMIA; MUSCLE CHANNELOPATHY; MUSCLE FIBER MEMBRANE; MUSCLE WEAKNESS; MYOTONIA; PERIODIC PARALYSIS; PHENOTYPE; REPOLARIZATION; SODIUM CHANNELOPATHY; SODIUM TRANSPORT; THOMSEN DISEASE; WATER TRANSPORT;

ANESTHETICS, LOCAL; ANTI-ARRHYTHMIA AGENTS; CHANNELOPATHIES; DIURETICS; DRUG THERAPY; HUMANS; MYASTHENIC SYNDROMES, CONGENITAL; MYOTONIA; PARALYSES, FAMILIAL PERIODIC;

EID: 78651434318     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lehmann-Horn, F, Rudel R, Jurkat-Rott K. In: Engel AG, FranziniArmstrong C, eds. Myology Ch. 46: Nondystrophic myotonias and periodic paralyses. 3rd edition. New York: McGraw-Hill 2004, pp. 1257-1300.
2. Lindstrom JM. Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology. Ann N Y Acad Sci 2003; 998; 41-52.
3. Chevessier F, Faraut B, Ravel-Chapuis A, et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol. Genet 2004;13:3229-40.
4. Ohno K, Engel AG, Shen XM, et al. Rapsyn mutations in humans cause endplate acetylcholine-receptor deficiency and myasthenic syndrome. Am J Hum Genet 2002; 70: 875-85. (Pubitemid 34259304)
5. Srour M, Bolduc V, Guergueltcheva V, et al. DOK7 mutations presenting as a proximal myopathy in French Canadians. Neuromuscul Disord 2010; 20: 453-7.
6. Deymeer F, Cakirkaya S, Serdaroglu P, et al. Transient weakness and compound muscle action potential decrement in myotonia congenita. Muscle Nerve 1998; 21: 1334-7.
7. Dupré N, Christian N, Bouchard JP, et al. Clinical, electrophysiologic, and genetic study of non-dystrophic myotonia in FrenchCanadians. Neuromuscul Disord 2009; 19: 330-4.
8. Bouhours M, Sternberg D, Davoine CS, et al. Functional characterization and cold sensitivity of T, a new mutation of the skeletal muscle sodium channel causing paramyotonia congenita in humans. J Physiol 2004; 554: 635-47.
9. Dice MS, Abbruzzese JL, Wheeler JT, et al. Temperature-sensitive defects in paramyotonia congenita mutants R1448C and T1313M. Muscle Nerve 2004; 30: 277-88.
10. Mohammadi B, Mitrovic N, Lehmann-Horn F, et al. Mechanisms of cold sensitivity of paramyotonia congenita mutation R1448H and overlap syndrome mutation M 1360V. J Physiol 2003; 547: 691-8. (Pubitemid 36367357)
11. Kubota T, Kinoshita M, Sasaki R, et al. New mutation of the Na channel in the severe form of potassium-aggravated myotonia. Muscle Nerve 2009; 39: 666-73.
12. Petitprez S, Tiab L, Chen L, et al. A novel dominant mutation of the Nav 1.4 (alpha)-subunit domain I leading to sodium channel myotonia. Neurology 2008; 71: 1669-75.
13. Stunnenberg BC, Ginjaar HB, Trip J, et al. Isolated eyelid closure myotonia in two families with sodium channel myotonia. Neurogenetics 2010; 11: 257-60.
14. Weber MA, Nielles-Vallespin S, Essig M, et al. Muscle Na+ channelopamies: MRI detects intracellular 23Na accumulation during episodic weakness. Neurology 2006; 67: 1151-8.
15. Webb J, Cannon SC. Cold-induced defects of sodium channel gating in atypical periodic paralysis plus myotonia. Neurology 2008; 70: 746-7.
16. Jurkat-Rott K, Mitrovic N, Hang C, et al. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci USA 2000; 97; 9549-54.
17. Struyk, AF, Cannon SC. A Na+ channel mutation linked to hypokalemic periodic paralysis exposes a proton-selective gating pore. J Gen Physiol 2007: 130: 11-20.
18. Sokolov S, Scheuer T, Catterall WA. Gating pore current in an inherited ion channelopathy. Nature 2007; 446: 76-8. (Pubitemid 46348048)
19. Tombola F, Paüiak MM, Isacoff EY. Voltage-sensing arginines in a potassium channel permeate and occlude cation-selective pores. Neuron 2005; 45: 379-88.
20. Jurkat-Rott K, Lehmann-Horn F. Do hyperpolarization-induced proton currents contribute to the pamogenesis of hypokalemic periodic paralysis, a voltage sensor channelopathy? J Gen Physiol 2007; 130: 1-5.
21. Jurkat-Rott K, Weber MA, Fauler M, et al. K+-dependent paradoxical membrane depolarization and Na+ overload, major and reversible contributors to weakness by ion channel leaks. Proc Natl Acad Sci USA 2009; 106: 4036-41.
22. Vicart S. New mutations of SCN4A cause a potassium-sensitive normokalemic periodic paralysis. Neurology 2004; 63: 2120-7. (Pubitemid 39636261)
23. Sokolov S, Scheuer T, Catterall WA. Depolarization-activated gating pore current conducted by mutant sodium channels in potassium-sensitive normokalemic periodic paralysis. Proc Natl Acad Sci USA 2008; 105: 19980-5.
24. Andelfinger G, Tapper AR, Welch RC, et al. KCNJ2 mutation results in Andersens syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 2002; 71: 663-8.
25. Wu S, Ibarra MC, Malicdan MC, et al. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 2006; 129: 1470-80. (Pubitemid 43999380)
26. Avila G, O'Brien JJ, Dirksen RT. Excitation-contraction uncoupling by a human central core disease mutation in the ryanodine receptor. Proc Nad Acad Sci USA 2001; 98: 4215-20.
27. Zhou H, Jungblum H, Sewry CA, et al. Molecular mechanisms and phenotypic variation in RYR1 -related congenital myopathies. Brain 2007; 130: 2024-36.
28. Alfonsi E, Merlo IM, Tonini M, et al. Efficacy of propafenone in paramyotonia congenita. Neurology 2007; 68: 1080-1.
29. Mohammadi B. Preferred mexiletine block of human sodium channels wiui IVS4 mutations and its pH-dependence. Pharmacogenet Genomics 2005; 15: 235-44.
30. Khadilkar SV, Singh RK, Mansukhani KA, et al. Relief from episodic weakness with pyridostigmine in paramyotonia congenita: a family study. Muscle Nerve 2010; 41: 133-7.
31. Tricarico D, Barbieri M, Camerino DC. Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis. Ann Neurol 2000; 48: 304-12.
32. Jurkat-Rott K, Holzherr B, Fauler M, et al. Sodium channelopathies of skeletal muscle result from gain or loss of function. Pflügers Arch - Europ J Physiol 2010; 460: 239-48.